Carcinoma, Hepatocellular
Conditions
Keywords
Immuncell-LC, Transarterial Chemoembolization
Brief summary
To evaluate the efficacy and safety of 'Immuncell-LC group' and 'non-treatment group' in the patients undergone Transarterial Chemoembolization for intermediate stage hepatocellular carcinoma
Detailed description
ILC-IIT-05 is randomized, open-label, multi-center phase 2 clinical trial. To confirm clinical efficacy and safety between 'Immuncell-LC group' and 'non-treatment group', primary outcome, recurrence free survival(RFS) will be evaluated. For secondary outcome, overall survival(OS), changes of Alpha Feto Protein(AFP), correlation of between myeloid-derived suppressor cell change and prognosis, adverse event, ECOG-PS and hematological examination will be evaluated.
Interventions
BIOLOGICALImmuncell-LC
Activated T lymphocyte : intravenous dripping of 200ml (1 x 10\^9 \ 2 x 10\^10 lymphocytes / 60kg adult) for 1 hour
Sponsors
GC Cell Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have consented to the study by providing signature of self * Patients who are more than 20 and less than 80 years old * Child-Pugh Class should be A(score 5-6) or B(score 7-8) * ECOG Performance Status (ECOG-PS) score is less than 1 or equal to * Patients who have been diagnosed with BCLC stage B hepatocellular carcinoma by pathological/radiological test(Dynamic contrast-enhanced CT or Dynamic MRI) and tumor removal has been confirmed after TACE (When patients have been diagnosed with recurrence of hepatocellular carcinoma after surgery or local treatment, if conditions are same as above, patients could be included) * Patients who satisfy the following conditions of the blood test and kidney, liver function test * Absolute neutrophil count \> 500/µL * Hemoglobin ≥ 8.5 g/dL * Platelet count \> 50,000/µL * Blood Creatinine ≤ 1.5xupper normal limit * Total bilirubin \< 3mg/dL * Albumin ≥ 2.8g/dL
Exclusion criteria
* Patients who have been confirmed with residual tumor or extrahepatic metastases * Patients who have lymph node metastases or portal vein, hepatic vein invasion * Patients who have a history of treatments or are in conditions as below * Liver transplantation * From Informed consent form sign date, systemic chemotherapy in 4 weeks or ongoing adverse drug reactions from anticancer drug in 6 weeks * External beam radiation, immunotherapy, molecular target therapy * More than 2 times of systemic chemotherapy * Biliary reconstruction or endoscopic biliary treatment * Patients who have a history of auto-immune diseases (Ex. Rheumatoid Arthritis, Systemic Lupus Erythematosus, Vasculitis, Multiple sclerosis, Adolescent Insulin-Dependent Diabetes Mellitus, etc.) * Patients who have a history of malignant tumors in the recent 5 years prior to the study except hepatocellular carcinoma * Patients who participated in another clinical trial and conducted treatment in 4 weeks or have a plan for administration of another clinical trial treatment since Informed consent form sign date * Patients who have uncontrollable or serious disease * Pregnant women or nursing mother * Patients who intend to get pregnant during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence Free Survival (RFS) | baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject | Every 12 weeks from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of Alpha Feto Protein (AFP) level | Every 12 weeks from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject | Every 12 weeks from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject |
| Correlation of between Myeloid-derived Suppressor Cell change and Prognosis | Every 12 weeks from the baseline until 4 weeks after the last dose of immunotherapy | Every 12 weeks from the baseline until 4 weeks after the last dose of immunotherapy |
| Overall Survival (OS) | baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject | Every 12 weeks from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject |
| Eastern Cooperative Oncology Group Performance Status (ECOG-PS) | From the time the patient provided written informed consent until drop-out or the end of the study or 4 weeks after the last dose of immunotherapy | From the time the patient provided written informed consent until drop-out or the end of the study or 4 weeks after the last dose of immunotherapy |
| Hematological examination | Every 12 weeks from the baseline until 4 weeks after the last dose of immunotherapy | Every 12 weeks from the baseline until 4 weeks after the last dose of immunotherapy |
| Adverse event | From the time the patient provided written informed consent until drop-out or the end of the study or at least 4 weeks after the last dose of immunotherapy | From the time the patient provided written informed consent until drop-out or the end of the study or at least 4 weeks after the last dose of immunotherapy |
Countries
South Korea
Outcome results
None listed